On Mar 4, 2026 AbbVie completed an $8.0B notes offering: $750M floating-rate due 2028; $1.5B 3.775% due…
Filed with the SEC on · Summarized by InvestorsBot
On Mar 4, 2026 AbbVie completed an $8.0B notes offering: $750M floating-rate due 2028; $1.5B 3.775% due 2028; $1.25B 4.125% due 2031; $1.25B 4.40% due 2033; $1.5B 4.75% due 2036; $1.25B 5.55% due 2056; $500M 5.65% due 2066. $ABBV 📣💵 #DebtOffering #Pharma
The offering was registered on Form S-3ASR. Notes governed by Base Indenture (Nov 8, 2012) + Supplemental Indenture No.12; U.S. Bank Trust Co., N.A. is trustee. Notes are unsecured, unsubordinated and pari‑passu with AbbVie’s other unsecured debt. $ABBV 🔖 #CorporateBonds #SEC
Redemption terms: make‑whole redemptions before Par Call Dates; after Par Call Dates (varies by series) fixed‑rate notes redeemable at 100% principal + accrued interest. Indenture includes customary limitations on liens and mergers. $ABBV 📌 #FixedIncome #Investing